Posted: 4 month(s) ago   |   0 Comment(s)   |   Rating: 0 0
Posted by: crwewallstreet.com

_______________________________________

FREE Daily Stock Alerts From CRWEWallStreet.com

_______________________________________

S3 Investment Company, Inc. (PINKSHEETS: SIVC) today commented on the status of its consolidated financial report for the period ended September 30, 2009, which were scheduled to be posted to the Pink Sheets OTC Disclosure and News Service this week. Due to the turnover in the company's accounting personnel, the quarterly financials will be delayed approximately 30 days and are expected to be filed by December 15, 2009.\

Power3 Medical Products, Inc. (OTCBB: PWRM), is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets.
Web Site: http://www.Power3Medical.com

CEL-SCI Corporation (NYSE Amex: CVM), a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late-stage oncology company, announced today the start of the Company's first clinical study for hospitalized H1N1 patients at The Johns Hopkins University School of Medicine (Johns Hopkins). The study is being led by Principal Investigator Jonathan M. Zenilman, MD, Professor of Medicine, Johns Hopkins School of Medicine and Chief of Infectious Diseases Division, Johns Hopkins Bayview Medical Center.

Aquentium, Inc. (OTCBB: AQNM) a company with a focus on "green technologies" announced that the company is now offering distributorship opportunities for its complete line of ozone sanitation and water treatment equipment for the Country of Bangladesh.
Website: http://www.aquentium.com

Nanosphere, Inc. (Nasdaq:NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, announced today it submitted a 510(k) application to the FDA for its cardiac troponin I test that the company believes will provide early and sensitive diagnosis of myocardial infarction and risk stratification for acute coronary syndromes.

************Advertisement************

************************************

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEWallStreet publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEWallStreet.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and has received an additional 1,000,000 shares 144 restricted stocks for 6 months of advertisement and diseminate news and $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Crown Equity Holdings, Inc. (CRWE.OB) is being paid 100,000 restricted shares for public relations services for Aquentium Inc. (AQNM).

Member Rating: 0 0